EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Severe Arboviral Neuroinvasive Disease in Patients on Rituximab Therapy: A Review

Ronak K Kapadia, J Erin Staples, Christine M Gill, Marc Fischer, Ezza Khan, Janeen J Laven, Amanda Panella, Jason O Velez, Holly R Hughes, Aaron Brault, Daniel M Pastula, Carolyn V Gould

Clinical Infectious Diseases · 21.03.2023 · 76 (6) · 1142-1148

DOI: 10.1093/cid/ciac766 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Infectious Diseases, online erschienen am 14.09.2022. Verfasst von Ronak K Kapadia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Infectious Diseases Group, Department of Neurology and Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colo…. Hauptthemen laut MEDLINE: West Nile Fever, Arbovirus Infections, Encephalitis, Tick-Borne. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With increasing use of rituximab and other B-cell depleting monoclonal antibodies for multiple indications, infectious complications are being recognized. We summarize clinical findings of patients on rituximab with arboviral diseases identified through literature review or consultation with the Centers for Disease Control and Prevention. We identified 21 patients on recent rituximab therapy who were diagnosed with an arboviral disease caused by West Nile, tick-borne encephalitis, eastern equine encephalitis, Cache Valley, Jamestown Canyon, and Powassan viruses. All reported patients had neuroinvasive disease. The diagnosis of arboviral infection required molecular testing in 20 (95%) patients. Median illness duration was 36 days (range, 12 days to 1 year), and 15/19 (79%) patients died from their illness. Patients on rituximab with arboviral disease can have a severe or prolonged course with an absence of serologic response. Patients should be counseled about mosquito and tick bite prevention when receiving rituximab and other B-cell depleting therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

West Nile FeverArbovirus InfectionsEncephalitis, Tick-BorneAnimalsRituximabDisease Outbreaks

Stichwörter der Autor:innen

anti-CD20arboviral diseasearbovirusmonoclonal antibodiesrituximab

Substanzen

Rituximab

Autor:innen und Institutionen

  • Neuro-Infectious Diseases Group, Department of Neurology and Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Division of Neurology, Department of Clinical Neurosciences, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.
  • University of Iowa, Carver College of Medicine, Department of Neurology, Iowa City, Iowa, USA.
  • Hunterdon Infectious Disease Specialists, Flemington, New Jersey, USA.
  • Department of Epidemiology, Colorado School of Public Health, Aurora, Colorado, USA.

Förderung

  • Intramural CDC HHS

Zitieren

APA

Kapadia, R. K., Staples, J. E., Gill, C. M., Fischer, M., Khan, E., Laven, J. J., Panella, A., Velez, J. O., Hughes, H. R., Brault, A., Pastula, D. M., & Gould, C. V. (2023). Severe Arboviral Neuroinvasive Disease in Patients on Rituximab Therapy: A Review. Clinical Infectious Diseases, 76(6), 1142-1148. https://doi.org/10.1093/cid/ciac766

Vancouver

Kapadia RK, Staples JE, Gill CM, Fischer M, Khan E, Laven JJ, et al. Severe Arboviral Neuroinvasive Disease in Patients on Rituximab Therapy: A Review. Clinical Infectious Diseases. 2023;76(6):1142-1148. doi:10.1093/cid/ciac766

BibTeX
@article{Kapadia2023,
  author = {Kapadia, Ronak K and Staples, J Erin and Gill, Christine M and Fischer, Marc and Khan, Ezza and Laven, Janeen J and Panella, Amanda and Velez, Jason O and Hughes, Holly R and Brault, Aaron and Pastula, Daniel M and Gould, Carolyn V},
  title = {Severe Arboviral Neuroinvasive Disease in Patients on Rituximab Therapy: A Review},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {76},
  number = {6},
  pages = {1142--1148},
  doi = {10.1093/cid/ciac766}
}
Kostenlos starten →